Blueprint Medicines (NASDAQ: BPMC) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Insider & Institutional Ownership

83.6% of Blueprint Medicines shares are owned by institutional investors. Comparatively, 16.8% of Medpace shares are owned by institutional investors. 3.4% of Blueprint Medicines shares are owned by insiders. Comparatively, 25.8% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Blueprint Medicines and Medpace’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Blueprint Medicines $27.77 million 119.72 -$72.49 million ($3.41) -22.74
Medpace $421.58 million 3.42 $13.42 million $0.68 56.47

Medpace has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Blueprint Medicines and Medpace’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Blueprint Medicines -437.83% -43.11% -34.38%
Medpace 6.44% 10.00% 6.19%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Blueprint Medicines and Medpace, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Blueprint Medicines 0 0 10 0 3.00
Medpace 0 6 1 0 2.14

Blueprint Medicines presently has a consensus target price of $83.78, indicating a potential upside of 8.06%. Medpace has a consensus target price of $35.75, indicating a potential downside of 6.90%. Given Blueprint Medicines’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Blueprint Medicines is more favorable than Medpace.

Volatility & Risk

Blueprint Medicines has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Medpace has a beta of -1.04, suggesting that its share price is 204% less volatile than the S&P 500.

Summary

Medpace beats Blueprint Medicines on 8 of the 14 factors compared between the two stocks.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Medpace Company Profile

Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.